ClinicalTrials.gg
Enrolling by invitationNCT07352618Updated Jan 21, 2026

"Effect of Omega-3 Supplementation as Add on Therapy on Glycemic Control and Lipid Profile in Type2 Diabetes Mellitus."

An interventional study of Omega-3 Fatty Acids and placebo in Type2 Diabetes Mellitus, sponsored by Bangladesh Medical University. Enrolling by invitation at 1 site in Bangladesh. Open to male participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Bangladesh Medical University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
25 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing omega-3 fatty acid in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, none of them phase 3. omega-3 fatty acid · Diabetes Mellitus, Type 2.

Planned enrollment
8th of 14
66 · median 77
Started
2026
with 1 other
No phase
7 of 14
3 open now
Registered
13th of 14
by date
Lead sponsor
1 of 14
Bangladesh Medical University

Among the 14 studies testing omega-3 fatty acid in Diabetes Mellitus, Type 2, this one is the 8th largest by planned enrollment, is one of 2 that started in 2026, is one of 7 with no phase, and was the 13th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 14 studies testing omega-3 fatty acid in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About omega-3 fatty acid

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 25 Years to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing omega-3 fatty acid in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if Omega-3 works to control glycemic status, improve lipid profile in Type2 Diabetic patients. It will also learn about the safety of drug Omega-3. The main questions it aims to answer are:

Does drug Omega-3 control glycemic status, improve lipid profile in Type2 Diabetic patients? What medical problems do participants have when taking drug Omega-3? Researchers will compare Omega-3 to a placebo(a look-alike substance that contains no drug)to see if Omega-3 works to treat Type 2 Diabetic patients.

Participants will take Omega-3 or a placebo twice daily for 12 weeks. Baseline and 12 weeks after FPG, HbA1c,Serum Lipid profile, Omega-3 level will be monitored.

Read the detailed description

Diabetes Mellitus is a common endocrine disorder. T2DM is characterized by polyuria, polydipsia, polyphagia. It affects both men and women. T2DM is strongly associated with impaired insulin sensitivity, insulin resistance, dyslipidaemia, hypertension, and central obesity. Omega-3 polyunsaturated fatty acid has been shown to exert beneficial effect on lipid metabolism and insulin sensitivity.

Aim of the study: We aimed to evaluate the effect of Omega-3 supplementation as add on therapy on glycemic control and lipid profile in Type 2 diabetes mellitus patients.

Methodology: This research will be a single center study, utilizing a double-blind, randomized placebo-controlled trial design. A total of 66 men and women, with diagnosed T2DM, age range from 25-75 years will randomly be assigned to receive either Omega-3 supplementation or placebo for 12 weeks. Biochemical and anthropometric measurements, including Fasting plasma glucose, HbA1c, lipid profile, blood pressure, BMI, waist-hip ratio and waist-to-height ratio will be assessed at baseline and post-treatment. Follow-up assessments will be conducted after supplementation for 12 weeks to evaluate the sustainability of biochemical changes. For independent samples; t-test will be utilized to analyze the average differences in metabolic biomarker levels between the group receiving Omega-3 supplements and the group receiving a placebo. The Chi-square test or Fisher's exact test will be employed to compare the percentage of participants may show a significant change in metabolic biomarker in the group that received Omega-3 versus the group that received a placebo.

Pearson or Spearman correlation tests will be used to explore any relationships between baseline Omega-3 levels and FPG, HbA1c and lipid profile levels, as well as between the change in Omega-3 levels and the change in FPG, HbA1c and lipid profile levels.

Conclusion: Combining Omega-3 supplementation with the conventional treatment could potentially have a substantial impact on lipid profile and glycemic control in patients with T2DM.

03

Conditions studied

  • Type2 Diabetes Mellitus
04

Who can participate

Ages eligible
25 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age above 25 years up to 75 years
  • Old and newly diagnosed case of Type2 DM.
  • Patient receiving conventional diabetic treatment like OAD or insulin or both
  • Patient may have altered lipid profile or not
  • Both male and female patient
  • Patient's level within 8.0%

Exclusion criteria

Exclusion Criteria:

  • Pregnancy and lactating mother.
  • History of known Type1 diabetes mellitus, secondary diabetes, drug induced diabetes, drugs interfering body weight.
  • Patient with acute illness, liver disease, psychiatric disorder
  • Patients receiving Omega-3 supplementation within the last three months.
  • Known allergy to fish oil or Omega-3 supplements.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Omega-3,

    Participant received Cap Omega-3 1gm orally twice daily for 12 weeks

    Dietary Supplement: Omega-3 Fatty Acids

  • Placebo comparator
    Placebo

    Participants received Omega-3 placebo capsule matching Omega-3 orally twice daily for 12 weeks

    Dietary Supplement: placebo

Interventions

  • Dietary supplementOmega-3 fatty acidStudies of Omega-3 fatty acidOmega-3 fatty acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants received Omega-3 1gm capsule orally twice daily for 12 weeks

  • Dietary supplementplacebo

    Participants received Omega-3 placebo capsule twice daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Changes in lipid profile

    (triglycerides, HDL-Cholesterol)

    Time frame: 12 weeks

  2. Change in Plasma Omega-3 level

    changes in plasma DHA and EPA conc

    Time frame: 12 weeks

  3. Change in HbA1c

    Time frame: 12 weeks

  4. Improvement of Fasting Plasma Glucose

    Time frame: 12 weeks

Secondary outcomes

  1. Change in Blood Pressure (Systolic and Diastolic Blood Pressure)

    Time frame: 12 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for May 2026, 4 months later.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 4 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2026
First posted
Jan 20, 2026
StartEst.
Jan 2026
Primary completionEst.
May 2026
CompletionEst.
Jun 2026
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07352618
Lead sponsor
Bangladesh Medical University
Responsible party
Dr. Toufique Tania Prity (Resident, Bangladesh Medical University) — Principal investigator
First posted
Jan 20, 2026
Start date
Jan 2026 (estimated)
Primary completion
May 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Jan 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omega-3 fatty acid

Start the discussion